The Alzinova Story
Alzinova AB is a clinical-stage biopharma company dedicated to developing both active and passive immunotherapies to treat Alzheimer’s disease.
The company was founded by scientists at the University of Gothenburg, Sweden, in 2011 after the invention of a unique technology platform, AβCC. The AβCC technology specifically stabilises disease-driving oligomers of the peptide amyloid-β (Aβ), thus enabling the development of disease-modifying therapeutics.
Business angels and the holding company at the University of Gothenburg, GU Holding AB (now GU Ventures AB), provided seed capital and business development support during the early years.
Johanna Hultgren, Björn Larsson, and Per Wester at the bell ringing ceremony during the first day of trading on Nasdaq First North.
In November 2015, Alzinova completed an IPO and was listed as a publicly traded company on Spotlight (previously ”AktieTorget”) in Sweden. In December 2018 a second round of share issuance was completed.
The new funding enabled the company to effectively move closer to clinical phase, preparing for the first clinical phase 1b study on it’s lead product, ALZ-101 – an active immunotherapy for the treatment of Alzheimer’s disease. ALZ-101 is now set to enter clinical phase 1.
Since March 2019, after completing a third capitalisation round, Alzinova is traded as a public company on the unregulated exchange list NASDAQ First North in Stockholm, Sweden (ticker: ALZ).
Learn more about the Alzinova portfolio and our proprietary AβCC Peptide™ Technology. Read more
Learn more about the causes of Alzheimer’s and the potential in our oligomer specific immunotherapy. Read more